15 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
dysfunction, cell toxicity, inflammation and the accumulation of alpha-synuclein (a hallmark of PD), which is toxic to neurons.
Indication Overview
PD
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
8 Jan 24
Regulation FD Disclosure
8:32am
gene, and may help to slow disease progression in ALS degrade toxic a-synuclein aggregates CK1δ phosphorylates TDP-43, a key NMDA PAMs can selectively
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
dysfunction, cell toxicity, inflammation and the accumulation of alpha-synuclein (a hallmark of PD), which is toxic to neurons.
Indication Overview
PD
S-1/A
EX-1.1
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have received and are in compliance with all … or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
toxicity, inflammation and the accumulation of alpha-synuclein (a hallmark of PD), which is toxic to neurons.
Indication Overview
PD
S-1
5e4le3zkll nb72
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.2
aafnw 385ajqige71ac2
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.1
jt10o
25 Aug 23
IPO registration
5:03pm
DRS/A
hpoiq1fk9blu8p
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
ifff3y zm8nej9
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
akl gsfjy
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
bxmcmvbfwj3kr33z8w
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
qqboq
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
aeuq51bw fk
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
xclemzfdglfcz
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next